Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IMS Foresees Generics Market Surging Ahead

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical research firm IMS expects the 2008 global pharmaceutical and health care industry to grow at 5 percent to 6 percent, a rate slightly less than the 6 percent to 7 percent of 2007. Drugs enjoying some $20 billion worth of sales will lose their patent this year, making space for generics to proliferate at 14 percent to 15 percent to reach over $70 billion, thanks to rising demand worldwide. Generics-producing countries such as China, Brazil, Mexico, South Korea, India, Turkey and Russia are set to expand their market at 12 percent to 13 percent to hit a total of $90 billlion in 2008. China, growing at 16 percent, ranks ninth on the global pharmaceutical market. IMS predicts that domestic demand will propel the country to sixth position in 2011. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel